Venous thromboembolic diseases: diagnosis, management and thrombophilia testing

benefits and risks of continuing, stopping or changing the anticoagulant with people who have had anticoagulation treatment for 3 months (3 to 6 months for people with active cancer) after a proximal DVT or PE. Follow the recommendations on shared decision making and supporting adherence in the NICE guidelines on medicines optimisation, medicines adherence and patient experience in adult NHS services. [2020] 1.4.2 Consider stopping anticoagulation treatment 3 months (3 to 6 months for people with active cancer) after a provoked DVT or PE if the provoking factor is no longer present and the clinical course has been uncomplicated. If anticoagulation treatment is stopped, give advice about the risk of recurrence and provide: • written information on symptoms and signs to look out for • direct contact details of a healthcare professional or team with expertise in thrombosis who can discuss any new symptoms or signs, or other concerns • information about out-of-hours services they can contact when their healthcare team is not available. [2020] 1.4.3 Consider continuing anticoagulation beyond 3 months (6 months for people with active cancer) after an unprovoked DVT or PE. Base the decision on the balance between the person's risk of VTE recurrence and their
